<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804267</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20078-501</org_study_id>
    <nct_id>NCT04804267</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Clinical Equivalence of Two Linaclotide Products and the Efficacy and Safety of the Test Formulation of Linaclotide in the Treatment of Chronic Idiopathic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the clinical equivalence of the test formulation&#xD;
      of Linaclotide compared to the marketed formulation LINZESS® in patients with Chronic&#xD;
      Idiopathic Constipation, and to evaluate the efficacy and safety of the test formulation of&#xD;
      Linaclotide in the treatment of Chronic Idiopathic Constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled, multicenter study to evaluate the&#xD;
      clinical equivalence of the test formulation of Linaclotide (manufactured by Jiangsu Hansoh&#xD;
      Pharmaceutical Co., Ltd.) compared to the marketed formulation LINZESS® in patients with&#xD;
      Chronic Idiopathic Constipation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of spontaneous bowel movements (SBM) during Week 1</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of 12-Week complete spontaneous bowel movements (CSBMs) overall responders</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of CSBM during Week 1 compared to baseline</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with a SBM within 24 hours of receiving the first dose</measure>
    <time_frame>24 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first SBM after the first dose</measure>
    <time_frame>up to 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with 12-Week CSBM frequency rate (CSBMs/week) ≥3</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 12-Week CSBM frequency rate (CSBMs/week)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 12-Week SBM frequency rate (SBMs/week)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-Week Stool Consistency Assessment (seven-point ordinal Bristol Stool Form Scale)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-Week Severity of Straining Assessment (five-point ordinal scale)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-Week Abdominal Discomfort Assessment (five-point ordinal scale)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-Week Bloating Assessment (five-point ordinal scale)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-Week Constipation Severity Assessment (five-point ordinal scale)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PAC-QOL score (Patient Assessment of Constipation Quality of Life questionnaire)</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Chronic Idiopathic Constipation</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linaclotide Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LINZESS® Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Drug: Placebo orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linaclotide</intervention_name>
    <description>Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LINZESS®</intervention_name>
    <description>Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo orally once daily</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or nonpregnant females aged ≥ 18 years with a clinical diagnosis of chronic&#xD;
             idiopathic constipation defined as &lt; 3 spontaneous bowel movements (SBMs) per week and&#xD;
             confirmed by daily diary during baseline period;&#xD;
&#xD;
        Have 1 or more of the following symptoms related to bowel movements for the past 3 months&#xD;
        with symptom onset at least 6 months before screening and confirmed by daily diary during&#xD;
        the 2-week baseline period:&#xD;
&#xD;
          -  lumpy or hard stools for more than 25% of the bowel movements (Bristol Stool Form&#xD;
             Scale 1 to 2)&#xD;
&#xD;
          -  sensation of incomplete evacuation following more than 25% of the bowel movements&#xD;
&#xD;
          -  straining at defecation more than 25% of the time Willing to discontinue any laxatives&#xD;
             used before the Pretreatment Visit in favor of the protocol-defined Rescue Medicine;&#xD;
             Agree to refrain from making any new major life-style changes that may have affected&#xD;
             CIC symptoms; Females of child-bearing potential have a negative pregnancy test prior&#xD;
             to beginning therapy and agree to use effective contraceptive methods during the study&#xD;
             and until 30 days after the last dose; Males who have partners of childbearing&#xD;
             potential agree to use effective contraceptive methods during the study and until 30&#xD;
             days after the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meet the Rome IV criteria for Irritable Bowel Syndrome or the Rome IV criteria for&#xD;
             Opioid-Induced Constipation; Have a potential central nervous system cause of&#xD;
             constipation (e.g., Parkinson's disease, spinal cord injury, and multiple sclerosis,&#xD;
             etc.); Have a structural abnormality of the gastrointestinal (GI) tract or a disease&#xD;
             or condition that can affect GI motility; Subjects with documented mechanical bowel&#xD;
             obstruction (e.g., bowel obstruction due to tumor, hernia), megacolon/megarectum, or&#xD;
             diagnosis of pseudo-obstruction; Have ever had a fecal impaction that required&#xD;
             hospitalization or emergency room treatment, or has a history of cathartic colon,&#xD;
             laxative or enema abuse, ischemic colitis, or pelvic floor dysfunction (unless&#xD;
             successful treatment has been documented by a normal balloon expulsion test); Subjects&#xD;
             with known or suspected organic disorders of the large or small bowel (e.g.,&#xD;
             inflammatory bowel disease, ulcerative colitis, Crohn's Disease); Subjects with&#xD;
             constipation secondary to a documented cause (e.g., surgery, bowel resection);&#xD;
             Diagnosis or family history of familial adenomatous polyposis, hereditary nonpolyposis&#xD;
             colorectal cancer, or any other form of familial colorectal cancer; Have a history of&#xD;
             cancer other than treated basal cell or squamous cell carcinoma of the skin in the&#xD;
             past 5 years; Have currently unexplained and clinically significant alarm symptoms&#xD;
             (lower GI bleeding [rectal bleeding or heme-positive stool], anemia, weight loss) or&#xD;
             systemic signs of infection or colitis; Have currently active peptic ulcer disease;&#xD;
             Have a history of diabetic neuropathy; Have untreated hypothyroidism or treated&#xD;
             hypothyroidism for which the dose of thyroid hormone has not been stable for at least&#xD;
             6 weeks at the time of the Screening Visit; Have a history of diverticulitis or any&#xD;
             chronic condition (e.g., chronic pancreatitis, polycystic kidney disease, ovarian&#xD;
             cysts, endometriosis) that can be associated with abdominal pain or discomfort and&#xD;
             could confound the assessments in this trial; Have clinically significant&#xD;
             cardiovascular, liver, lung, neurologic, renal or psychiatric disorder, or clinically&#xD;
             significant laboratory abnormalities, ineligible to participate in the study as&#xD;
             determined by the investigator; Have a history of drug or alcohol abuse in the past 12&#xD;
             months before screening; Bariatric surgery for treatment of obesity or surgery to&#xD;
             remove a segment of the GI tract at any time before screening; any gastrointestinal or&#xD;
             abdominal surgical procedure during the 3 months before screening; any other major&#xD;
             surgery during the 30 days before screening; Use of systemic antibiotics within 4&#xD;
             weeks prior to enrolment; Unwilling or unable to abide by the restrictions regarding&#xD;
             use of prohibited medicines; Have received any investigational drug during the 3&#xD;
             months before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jingyuan Fang, MD</last_name>
    <phone>86-021-53882001</phone>
    <email>fangjingyuan_new@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital, Medical Collge of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingyuan Fang, Doctor</last_name>
      <phone>86-021-53882001</phone>
      <email>fangjingyuan_new@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linaclotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

